Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers

NCT03674424 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT03674424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03674424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers
Lead sponsor
Jules Bordet Institute
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2018
Completion date
January 30, 2025
Enrollment
137 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

non-metastatic muscle invasive bladder cancer